Wednesday 13:00-13:45, Hall 8
Despite considerable advances in the medical management of ulcerative colitis (UC) there remain several areas of unmet need for UK patients and physicians. These include a lack of response and/or intolerance to current therapies, achieving a rapid onset of clinical effect, maintaining long term steroid free remission, and incorporating individual patient goals into disease management within the NHS.
- JAK1 preferential inhibition: what does it mean?
- Clinical relevance of filgotinib in moderate to severe UC
- Managing moderate to severe UC patients with filgotinib
Professor Miles Parkes, Consultant Gastroenterologist, Addenbrookes NHS Trust Hospital, Cambridge
Dr Alissa Walsh DPhil FRACP, Consultant Gastroenterologist, Oxford University Hospitals NHS Trust, Oxford
Lisa Younge, Nurse Consultant – Inflammatory Bowel Disease, London North West University Hospital NHS Trust